|[May 08, 2014]
Research and Markets: Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014: 178 Companies Plus Partners Developing 197 Wnt Pathway Targeting Drugs in 677 Developmental Projects
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/frv6bh/wnt_signaling)
has announced the addition of the "Wnt
Signaling Pathway in Oncology Drug Pipeline Update 2014" report
to their offering.
Abnormalities in the Wnt signaling pathway are associated with a large
variety of human malignancies including tumors of breast, colon,
pancreas, liver and bone.
There are today 178 companies plus partners developing 197 Wnt pathway
targeting drugs in 677 developmental projects in cancer. In addition,
there are 3 suspended drugs and the accumulated number of ceased drugs
over the last years amount to another 103 drugs.
Wnt Signaling Pathway In Oncology Drug Pipeline Update lists all drugs
and gives you a progress analysis on each one of them. Identified drugs
are linked to 190 differet targets. All included targets have been
cross-referenced for the presence of mutations associated with human
cancer. To date 186 out of the 187 studied drug targets so far have been
recorded with somatic mutations.
The software application lets you narrow in on these mutations and links
out to the mutational analysis for each of the drug targets for detailed
information. All drugs targets are further categorized on in the
software application by 41 classifications of molecular function and
with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Includes more than 178 principal companies plus their collaborators.
There is direct access from inside the application to web pages of all
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 197 Wnt pathway targeting drugs in
development, which have a total of 677 developmental projects in
cancer. In addition there are suspended and ceased drugs.
Included Wnt pathway targeting drugs are also in development for 127
other indications, where of 94 are different cancer indications.
Pipeline Breakdown According to Number of Drugs
Marketed # 10
Registered # 1
Pre-registration # 2
Phase III # 16
Phase II # 60
Phase I # 73
Preclinical # 127
No Data # 3
Suspended # 3
Ceased # 103
For more information visit http://www.researchandmarkets.com/research/frv6bh/wnt_signaling
[ Back To Homepage ]